奥莱阿诺酸通过减轻肠道衰老来改善5-甲诱导的肠损伤和炎症
Shi-Rui Bai1, Bing-Xiang Zhao1, Qi Zhao1
1School of Basic Medicine, Dali University, Dali, 671000, Yunnan, China.
Scientific reports
|September 19, 2024
概括
醇酸 (OA) 通过减少衰老细胞和炎症来减少化疗的副作用. 甲酸还增强了5-Fluorouracil (5-FU) 对结直肠癌的疗效,提供了一种高效,低毒性的治疗选择.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 5-甲 (5-FU) 是一种标准的结肠直肠癌 (CRC) 治疗方法,但会导致严重的副作用,如腹和肠道损伤.
- 衰老细胞增加与5-FU诱导的肠损伤相关,抗衰老药物可以减轻这些影响.
- 烯酸 (OA) 是一种五环三烯酸,已知具有保护作用,但其在衰老中的作用仍然未被探索.
研究的目的:
- 为了研究醇酸 (OA) 对5-Fluorouracil (5-FU) 诱导的细胞衰老和肠道损伤的影响.
- 在结直肠癌模型中探索OA在减轻5-FU副作用和增强其抗癌疗效方面的潜力.
主要方法:
- 在实验室模型中使用了人静脉内皮细胞 (HUVEC) 和肠道细胞 (NCM460),接受了5-FU.
- 评估了衰老标志物 (SA-β-gal活性,p16,p53,p21) 和与衰老相关的分泌表型 (SASP).
- 采用BALB/c小鼠模型来评估5-FU诱导的肠损伤,衰老细胞增加和OA的治疗效果.
- 通过mTOR抑制研究了OA的机制及其对5-FU的结肠癌细胞系 (HCT116,SW480) 的影响.
主要成果:
- 在体外,OA通过降低SA-β-gal活性和关键衰老标志物 (p16,p53,p21) 和SASP (IL-1β,IL-6,IL-8,IFN-γ,TNF-α) 来显著改善5-FU诱导的衰老.
- 在体内,OA治疗缓解了5-FU诱导的肠道炎症和损伤,与减少的衰老细胞群相关.
- OA通过抑制mTOR和增强5-FU对结肠癌细胞的细胞毒性作用来表现出老化作用.
结论:
- 醇酸 (OA) 有效地抵消由5-Fluorouracil (5-FU) 诱导的细胞衰老和肠道损伤.
- 氧化是一种有前途的治疗策略,可减轻化疗副作用,改善结直肠癌治疗结果.
- 这项研究强调了OA作为一种潜在的辅助疗法,用于高效,低毒性结直肠癌治疗.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
129
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
129
Drugs Affecting GI Tract Motility: Other Laxatives
173
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
173
Drugs for Treatment of Constipation-Predominant IBS
143
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
143
Drugs for Treatment of Diarrhea-Predominant IBS
152
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
152
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
414
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
414
Factors Influencing Drug Absorption: Disease States and Pharmacology
463
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
463


